Identification of Cognitive and Motor Changes in Individuals With and Without Parkinson's Disease Using Hemoencephalography
NCT07931677, Completed, Federal University of Uberlandia
Trial 8
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Identification of Cognitive and Motor Changes in Individuals With and Without Parkinson's Disease Using Hemoencephalography | ClinicalTrials.gov |
| NCT number | NCT07931677 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Enrollment | 46 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Federal University of Uberlandia | ClinicalTrials.gov |
| Conditions | Parkinson Disease | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Prefrontal hemoencephalography during the Box and Block Test | 12 months | Prefrontal HEG index (dimensionless value reported by the device; no physical unit), expressed as the change from rest to task. | ClinicalTrials.gov |
| Primary | Prefrontal hemoencephalography during the Nine-Hole Peg Test | 12 months | Prefrontal HEG index (dimensionless value reported by the device; no physical unit), expressed as the change from rest to task. | ClinicalTrials.gov |
| Primary | Prefrontal hemoencephalography during the Trail Making Test part A | 12 months | Prefrontal HEG index (dimensionless value reported by the device; no physical unit), expressed as the change from rest to task. | ClinicalTrials.gov |
| Primary | Prefrontal hemoencephalography during the Trail Making Test part B | 12 months | Prefrontal HEG index (dimensionless value reported by the device; no physical unit), expressed as the change from rest to task. | ClinicalTrials.gov |
| Primary | Prefrontal hemoencephalography during spiral and sinusoid drawing | 12 months | Prefrontal HEG index (dimensionless value reported by the device; no physical unit), expressed as the change from rest to task. | ClinicalTrials.gov |
| Primary | Box and Block Test | 12 months | Number of blocks transferred in 60 seconds. Higher scores mean a better outcome. | ClinicalTrials.gov |
| Primary | Nine-Hole Peg Test | 12 months | Time in seconds to place and remove nine pegs. Higher values mean a worse outcome. | ClinicalTrials.gov |
| Primary | Trail Making Test part A | 12 months | Time in seconds to complete part A. Higher values mean a worse outcome. | ClinicalTrials.gov |
| Primary | Trail Making Test part B | 12 months | Time in seconds to complete part B. Higher values mean a worse outcome. | ClinicalTrials.gov |
| Primary | Pen speed during drawing | 12 months | Pen speed during spiral and sinusoid drawings, measured from the task videos, in percentage of the sheet size per second. | ClinicalTrials.gov |
| Primary | Drawing duration | 12 months | Time in seconds to complete the spiral and sinusoid drawings, measured from the task videos. | ClinicalTrials.gov |
| Primary | Drawing smoothness (spectral arc length) | 12 months | Spectral arc length (SPARC) of the pen trajectory during spiral and sinusoid drawings, measured from the task videos. Dimensionless; more negative values indicate less smooth movement. | ClinicalTrials.gov |
| Primary | MDS-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS III) | First and last sessions (12 months) | Clinical scale of motor signs of Parkinson's disease, applied to the experimental group. Each item is rated from 0 (normal) to 4 (severe); higher scores mean a worse outcome. | ClinicalTrials.gov |
| Primary | Hoehn & Yahr scale | First and last sessions (12 months) | Stage of Parkinson's disease (1 to 5), applied to the experimental group. Higher stages mean a worse outcome. | ClinicalTrials.gov |
| Primary | Parkinson's Disease Questionnaire (PDQ-39) | First and last sessions (12 months) | Disease-specific quality of life, applied to the experimental group. Summary index from 0 to 100; higher scores mean a worse outcome. | ClinicalTrials.gov |
| Primary | Cognition (Mini-Mental State Examination) | Baseline | Screening score from 0 to 30. Higher scores mean a better outcome. | ClinicalTrials.gov |
| Primary | Visual acuity | Baseline | Visual acuity measured with the Snellen test | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)